What Happened?
Bala Cynwyd, PA-based LaserLock Technologies has Appointed Paul Donfried as Chief Technology Officer
About the Company
Like so many of history’s greatest companies, LaserLock’s focus has evolved over time. Today, we are leading the development of cutting-edge authentication and anti-counterfeiting technologies. The timing couldn’t be any more important. In an age of global chaos, a major source of funding for terrorist groups and organized crime is counterfeiting. Every day, consumers unknowingly purchase counterfeit products from legitimate vendors, and perpetuate a global system of thievery and destruction. And when these groups turn to counterfeiting currency or pharmaceuticals, they’re not just eating away at someone’s bottom line. Instead, they are holding hostage the national security and public health of people around the world. LaserLock’s mission is simple – to protect consumers, companies and governments from the dangers of the global counterfeiting trade. By offering cost-effective solutions that authenticate products, documents and people more effectively than ever before, LaserLock will continue to be a global leader in the fight against counterfeit goods.
About the Person
Paul Donfried has been Chief Technology Officer of LaserLock Technologies Inc. since January 29, 2013. Mr. Donfried supports the LaserLock Technologies's overall mission of providing anti-counterfeiting and brand-protection product solutions. He also manage both internal and external IT. For the past three years, Mr. Donfried has served as Chief Technology Officer for Identity & Access Management at Verizon. Prior to joining Verizon, Mr. Donfried served as the Vice President for SAIC Identity & Access Management Solutions where he worked with some of the world's largest pharmaceutical companies. Mr. Donfried has more than 20 years of experience in identity protection and authentication to LaserLock Technologies. His career includes nearly a decade of developing the SAFE-Biopharma Association, which focused on legally enforceable digital signatures for U.S. Food and Drug Administration (FDA) submissions. His work includes developing and implementing a global enterprise I&AM infrastructure and a policy-driven, standards-based approach to global, legally enforceable digital signatures called SAFE.
Info Source
News
Short Profile